Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609574 | 0.81 | GABRA1 (0.35) | GABRA1GABRB2ACLYPOLBGAA | |
| SCHEMBL15836404 | 0.77 | POLB (0.37) | GABRA1GABRB2POLBACHE | |
| SCHEMBL17449150 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2POLBACHE | |
| SCHEMBL16849224 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2POLBACHE | |
| SCHEMBL10183607 | 0.77 | GABRA1 (0.52) | GABRA1GABRB2ACLYPOLBGAA | |
| SCHEMBL16956189 | 0.77 | TSHR (0.50) | TRPV4 | |
| SCHEMBL803437 | 0.77 | TSHR (0.50) | GABRA1GABRB2ACLYPOLBGAA | |
| SCHEMBL18077876 | 0.75 | HMGCR (0.36) | GABRA1GABRB2POLBACHE | |
| SCHEMBL15537637 | 0.75 | GABRA1 (0.33) | GABRA1GABRB2POLBACHE | |
| SCHEMBL13466014 | 0.75 | RORC (0.35) | GABRA1GABRB2ACLYGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | GABRA1 3096/4885GABRB2 3307/4885ACLY 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.